肿瘤内科 预约挂号在线咨询

学科带头人: 潘宏铭 教授， 主任医师地理位置: 庆春院区 门诊：1号楼2楼门诊西区； 住院病区：1号楼12楼 下沙院区 门诊： 门诊住院大楼2楼第四诊区； 住院病区：12楼东区、西区电 话: （0571）86006926 电子邮件:shonco@sina.cn[科室简介]肿瘤内科创建于1995年，是国家重点学科-肿瘤学的一部份，在中美专家的联合指导下，已迅速发展成为目前浙江省规模大、综合实力强的肿瘤内科。目前月出院病人数已突破600人次，住院病人的人均次费用居同类医院中低。拥有高级职称9人，其中博士生导师2名，硕士生导师4名。博士学历14人，硕士学历10人。已经培养了大量的博士、硕士研究生和进修医师，成为了浙江省肿瘤内科人才培养的重要基地。本科还承担了60余项全球国际多中心药物临床研究，配备临床试验PI助理2人，肿瘤随访医师1人。1996年开始在美国专家的指导下，每周三与肿瘤中心各科室联合举办多学科诊治讨论（MDT），在肿瘤患者个体化治疗领域站在了国内前沿。并与本院分子病理中心联合开展Her-2、EGFR、EML4-ALK、C-Kit、cMET、k-Ras、BRAF、MSI等数十个分子靶点基因的检测，是浙江省较强的、较规范的基因检测中心。拥有省内肿瘤内科雄厚的科研实力，目前已经承担了国家自然科学基金9项，省科技厅重大专项1项，12项省部级科学基金等，为肿瘤转化医学的研究应用于临床提供强有力的后盾。本学科是国内较早开展肿瘤射频消融治疗的单位之一，尤其对于肺部、肝脏近膈顶部等特殊疑难部位肿瘤的射频治疗积累了丰富经验；在浙江省科技厅重大科研项目“基于纳米材料技术研制新型射频治疗针及其在肺部肿瘤治疗中的应用”的研究工作取得重大进展。潘宏铭主任主持制订了《中国肿瘤营养治疗专家共识》、《浙江省射频消融技术治疗规范》，是浙江省肿瘤射频消融质量控制中心，首批高分通过国家卫健委“癌痛规范化治疗示范病房”。2012年9月20日国家卫健委“癌痛规范化治疗示范病房”现场经验交流会在我院举行，全国90多家三甲医院领导及专家来我院现场观摩，受到了一致好评。[学术地位]潘宏铭 主任医师，博士生导师，国家卫健委合理用药专家委员会委员国家卫健委胃癌诊治规范制定专家， 全国医师定期考核委员会专家，国家食品药品监督管理局国家新药审评专家，中国临床肿瘤学会（CSCO）常委，浙江省抗癌协会常委兼肿瘤化疗专委会主任委员， CSCO中国临床肿瘤科学基金管理委员会委员，CSCO肿瘤营养治疗专家委员会主任委员， CSCO脑转移瘤专家委员会副主任委员， CSCO血管靶向治疗专家委员会委员，CSCO肝癌专家委员会委员，CSCO黑色素瘤专家委员会委员，中国抗癌协会肿瘤化疗专业委员会委员，美国临床肿瘤学会（ASCO）高级会员，中国抗癌协会癌症康复与姑息治疗专业委员会委员，浙江省药理学会理事。王娴 主任医师，浙江省抗癌协会肿瘤转移专业委员会常委，浙江省抗癌协会化疗专业委员会委员浙江省医学会肿瘤学分会青年委员浙江省抗癌协会乳腺癌专业委员会委员浙江省免疫学会肿瘤免疫和生物治疗专业委员委员，浙江省细胞生物学会医学细胞生物专业委员委员，AACR会员国家自然科学基金同行评议专家，International Journal of Cancer、Chinese-German Journal of Clinical Oncology 等杂志评审专家，World Journal of Gastrointestinal endoscopy 编委 。方勇 主任医师，浙江省抗癌协会肿瘤化疗专业委员会秘书、委员、青年副主任委员。楼海舟 主任医师 浙江省抗癌协会化疗专业委员会青年委员，大肠癌专业委员会青年委员。李达 主任医师 浙江省抗癌协会肿瘤生物治疗专业委员会秘书、委员 浙江省抗癌协会肿瘤化疗专业委员会青年委员郑宇 副主任医师 浙江省抗癌协会肿瘤化疗专业青年委员会秘书韩卫东 副研究员 浙江省抗癌协会肿瘤标记物专业委员会青年委员[学科带头人]潘宏铭 教授，主任医师国家新药审评专家，中国临床肿瘤学会常委，中国肿瘤营养治疗专家委员会主任委员，浙江省抗癌协会理事兼肿瘤化疗专委会副主委，浙江省药理学会理事。[诊疗范围]各种晚期实体肿瘤尤其是肺癌、食管癌、胃癌、结直肠癌、肝癌、乳腺癌、卵巢癌、淋巴瘤、胰腺癌、子宫内膜癌、宫颈癌、恶性黑色素瘤、神经内分泌肿瘤、不明来源恶性肿瘤的化疗及分子靶向药物治疗。原发及转移性肺癌、肝癌的射频消融治疗。同时还负责肿瘤患者营养治疗、癌痛的规范化治疗、肿瘤分子免疫治疗。并负责全球多中心的药物临床研究。科室 主任: 潘宏铭科室副主任: 王娴、方勇、李达、韩卫东专 家: 潘宏铭 方勇 王娴 楼海舟 郑宇 李达 韩卫东 潘勤 楼芳 胡泓 寿佳威1. 原发性及转移性肝癌、肺癌的微创治疗（射频消融）2. 恶性肿瘤的早期诊断，筛查和预防3. 晚期乳腺癌的化疗、分子靶向治疗; 乳腺癌的围手术治疗4. 晚期肺癌的化疗、分子靶向治疗5. 晚期胃癌的个体化综合治疗；胃癌的围手术治疗6. 晚期结直肠癌的个体化综合治疗；结直肠癌的围手术治疗7. 晚期肝癌的个体化综合治疗8. 不明来源肿瘤的多学科联合诊治9. 晚期癌痛的个体化治疗10. 晚期肿瘤患者的营养治疗11. 国际多中心抗肿瘤药物临床研究1. 科室以“微创”和个体化治疗为主导，以建设国内实体肿瘤个体化治疗专科为发展目标，将微创技术和个体化治疗全面应用于实体肿瘤治疗各个领域，包括肺癌、乳腺癌、胃癌、肝癌、结直肠癌、胰腺癌等。本学科是国内较早开展肿瘤射频消融治疗等单位之一，尤其对于肺部、肝脏近膈顶等特殊疑难部位肿瘤等射频消融治疗有丰富等经验，目前是浙江省射频消融质量控制中心。2. 与本院病理科联合开展Her-2、EGFR、EML4-ALK、C-Kit、cMET、k-Ras、BRAF、MSI等20多个分子靶点的基因诊断项目，每周三与肿瘤中心各科室联合举办多学科诊治讨论（MDT），在肿瘤患者个体化治疗领域站在了国内前沿。3. 拥有省内肿瘤内科雄厚的科研实力，目前已经承担了国家自然科学基金9项，省科技厅重大专项1项，12项省部级科学基金等，为肿瘤转化医学的研究应用于临床提供强有力的后盾。4. 推动包括“癌痛规范化示范病房”在内的肿瘤规范化治疗，成为国家卫健委首批创建“癌痛规范化治疗示范病房”。5. 主持制订《中国恶性肿瘤患者营养支持与治疗的专家共识》。基础研究方向应用技术研究本学科是国内较早开展肿瘤射频消融治疗的单位之一，尤其对于肺部、肝脏近膈顶部等特殊疑难部位肿瘤的射频治疗积累了丰富经验；在浙江省科技厅重大科研项目“基于纳米材料技术研制新型射频治疗针及其在肺部肿瘤治疗中的应用”的研究工作取得巨大进展；潘宏铭主任主持制订了《浙江省射频技术治疗肝脏肿瘤诊疗规范》；目前是浙江省肿瘤射频消融质量控制中心。论著潘宏铭，徐农主编. 《肿瘤内科临床治疗与合理用药》。中国科学技术文献出版社，2007年2月出版.《肿瘤化疗的毒副反应和防治》《肿瘤内科诊治策略》《肿瘤内科合理治疗和用药技巧》Wang X and Jin H. The epigenetic aspect of gastric carcinoma. Gastric Carcinoma 2011 InTechJin H, Ma Y, Shen Q and Wang X. Circulating methylated DNA as biomarkers of cancer detection. Methylation 2012 InTech译著药物基因组学 浙江大学出版社胰腺癌 人民卫生出版社专利申请异丹叶大黄素在制备抗肿瘤活性药物中的应用 CN201310102469.1 1/3甲基化SLC19A3基因的应用 ZL 2011 1 0048270.6 1/4SLC19A3基因在制备抗癌产品中的应用 2011040100131770 1/4FBP1基因的应用 201110365274.7 2/3甲基化FBP1基因的应用 201110375454.3 2/3科学研究主要论文1. Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, Wang K, Pan H*. Comparison of Long-term Effectiveness and Complications of Radiofrequency Ablation with Hepatectomy for Small Hepatocellular Carcinoma. J Gastroenterol Hepatol. 2014; 29(1):193-200. IF：3.3322. Fang Y, Cao Z, Hou Q, Ma C, Yao C, Li J, Wu XR, Huang C. Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells. Mol Cancer Ther. 2013;12(8):1492-503. IF：5.32.3. Fang Y, Yu Y, Hou Q, Zheng X, Zhang M, Zhang D, Li J, Wu XR, Huang C. The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP. J Biol Chem. 2012; 287(42):35234-43. IF:4.74. Sui X, Na Kong, Wang Z, Pan H*. Epigenetic regulation of hTERT：a potential therapeutic targets for the treatment of leukemia. Oncol Lett 2013，8（6）:317-322. IF:0.2375. Sui X, Chen R, Wang Z, Kong N, Huang Z, Zhang M, Han W, Wang X*, He C*, Pan H*. Autophagy and Chemotherapy Resistance: A Promising Therapeutic Strategy for Cancer. Cell death and disease. 2013; 4:e838. IF:6.0446. Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, He C, Pan H*. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer lett. 2013; 3835:831-838. IF:4.2587. Sui X, Jin L, Huang X, Geng S, He C, Hu X. p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment. Autophagy 2011; 7(6):565-71. IF:12.0428. Sui X, Wang D, Geng S, Zhou G, He C, Hu X. Methylated promoters of genes encoding protocadherins as a new cancer biomarker family. Mol Biol Rep 2012; 39(2):1105-11. IF:2.5069. Hu X, Sui X, Li L, Huang X, Rong R, Su X, Shi Q, Mo L, Shu X, Kuang Y, Tao Q, He C. Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. J Pathol 2013; 229(1):62-73. IF:7.58510. Klionsky DJ, Abdalla FC, ,,,,Sui X,,,,, Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012; 8(4):445-554. IF:12.04211. Pan H*, Cai S, Ji J, Jiang Z, Liang H, Lin F, Liu X. The impact of nutritional status, nutritional risk, and nutritional treatment on clinical outcome of 2248 hospitalized cancer patients: a multi-center, prospective cohort study in Chinese teaching hospitals. Nutr Cancer. 2013 Jan;65(1):62-70 IF：2.6912. Xu Y, Xia X, Pan H*. Active autophagy in the tumor microenvironment: A novel mechanism for cancer metastasis. Oncol Lett. 2013 Feb;5(2):411-416. Epub 2012 Nov 7.13. Han W, Xie J, Fang Y, Wang Z, Pan H*. Nec-1 Enhances Shikonin-Induced Apoptosis in Leukemia Cells by Inhibition of RIP-1 and ERK1/2. Int J Mol Sci. 2012;13(6):7212-25. Epub 2012 Jun 12. IF:2.279 314. Han W, Sun J, et al and Pan H*. Autophagy Inhibition Enhances Daunorubicin-Induced Apoptosis in K562 Cells. PLoS ONE, 2011;6(12). Epub 2011Dec 3. IF:4.41 1615. Han W, Pan H*, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS ONE. 2011;6(6):e18691. Epub 2011 Jun 2. IF:4.41 3416. Wang K, Pan H*, Lou H, Sheng L, Zhu X. Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia. BMC Cancer. 2011 May 27;11:204.IF:3.15317. Pan H, Fu X, Huang W*. Review: Molecular mechanism of liver cancer. Anticancer Agents Med Chem. 2011;11(6):493-9. IF:1.62318. Sui X, Kong N, Zhu M,Wang X, Lou F, Han W*, Pan H*. Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non small cell lung cancer (Review). Molecular and clinical oncology. 2013; 18:8-12.19. Zhang Y, Pan H*. Advanced adenoid carcinoma of the parotid gland treated with surgery chemotherapy and targeted therapy. HealthMED - Volume 7 / Number 4 / 201320. Da Li, Yin Kong, Hai Yu, Hongliang Huang, Lijing Min, Jun Zhou, Qingqing Wang and Guping Tang. The construction of a novel kind of non-viral gene delivery vector based on protein as core backbone. Vox Sanguinis. 2008，94(3)：234-241.（2008 IF 2.8）21. Li D, Ping Y, Xu F, Yu H, Pan H, Huang H, Wang Q, Tang G, Li J. Construction of a star-shaped copolymer as a vector for FGF receptor-mediated gene delivery in vitro and in vivo. Biomacromolecules. 2010，11(9):2221-9.（2010 IF 5.3）22. Shen Q, Yao Q, Sun J, Feng L, Lu H, Ma Y, Liu L, Yue Y, Li J, Wang F, Jin H*, Wang X*. Down-regulation of Histone Deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin FEBS Letters 2013 *: 通讯作者 (IF:3.6)23. Lu H, Li G, Liu L, Feng L, Wang X* and Jin H. Regulation and function of mitophagy in development and cancer Autophagy 2013;9(11):1-17 *: 通讯作者 (IF: 12.2)24. Lan T, Wang L, Xu Q, Liu W, Jin H, Mao W, Wang X*, Wang XJ*. Growth inhibitory effect of Cucurbitacin E on breast cancer cells Int J Clin Exp Pathol 2013;6(9):1799-805*: 通讯作者 (IF: 2.2)25. Wang X, Zhang S, Zhang J, Lam E, Liu X, Sun J, Feng L, Lu H, Yu J, Jin H* Annexin A6 is downregulated through promoter methylation in gastric cancer American Journal of Translational Research 2013;5(5):555-6226. Lu H, Sun J, Wang F, Feng L, Ma Y, Shen Q, Jiang Z, Sun X, Wang X*, Jin H*. Enhancer of zeste homologue 2 activates wnt signaling through downregulating CXXC finger protein 4 2013; 4:e776 Cell Death & Disease 2013 *: 通讯作者 (IF: 6.0)27. Shen Q, Jin H and Wang X*. Epidermal stem cells and their epigenetic regulation Int. J. Mol. Sci 2013;14(9):17861-80 (IF: 2.1)28. Feng L, Pan M, Sun J, Lu H, Shen Q, Zhang S, Jiang T, Liu L, Jin W, Chen Y, Wang X*, Jin H*. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. Journal of Molecular Medicine 2013;91(1):49-58 *: 通讯作者 (IF: 5.2)29. Wang Y, Ding L, Wang X*, Zhan J, Han W, Feng L, Sun J, Jin H and Wang XJ*. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells American Journal of Translational Research 2012;4(1):44-51 *: 通讯作者30. Wang L, Wang X*, Wang XJ, Pan J, Lu HQ, Zhang SJ, Lin XY, Lam EK, Cui Y, Yu J and Jin HC*. Klotho is silenced through promoter hypermethylation in gastric cancer American Journal of Cancer Research 2011;1(1):111-119 *: 通讯作者31. Lam EK, Wang X*, Shin V, Zhang S, Morrison H, Sun J, Ng EK, Yu J and Jin H*. A microRNA contribution to aberrant Ras activation in gastric cancer. American Journal of Translational Research 2011;3(2):209-218 *: 通讯作者32. Feng LF, Wang X* and Jin HC*. Rabbit monoclonal antibody: potential application in cancer therapy American Journal of Translational Research 2011;3(3):269-274 *: 通讯作者33. Pan J, Zhong J, Gan LH, Chen SJ, Jin HC, Wang X*, Wang LJ*. Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer Tumor Biology 2011;32(4):729-735 *: 通讯作者 (IF: 2.2)34. Wang X and Jin H. The epigenetic basis of Warburg effect Epigenetics 2010; 5(7):566-568 (IF: 4.5)35. Liu X*, Wang X*, Zhang J, Lam EK, Shin VY, Cheng AS, Yu J, Chan FK, Sung JJ and Jin HC. Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis Oncogene 2010;29:442-450 (IF: 7.2) *: 共同第一作者36. Wang X, Lau KK, So LK and Lam YW. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. Journal of Biomedical Science 2009;Oct 19;16:95 (IF: 2.0)37. Wang X, Lam EK, Zhang JB, Jin HC and Sung JJ. MicroRNA-122a functions as a novel tumor suppressor downstream of adenomatous polyposis coli in gastrointestinal cancers Biochem Bioph Res Com 2009; Jun 14;387(2):376-380 (IF: 2.7)38. Jin H.*, Wang X.*, Wong AHY, Chan ATC, Tao Q. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene, 2007;Nov 22;26(53):7490-8 (IF: 7.2) *: 共同第一作者39. Wang X. and Johnsson N. Protein kinase CK2 phosphorylates Sec63p to stimulate the assembly of the endoplasmic reticulum protein translocation apparatus. Journal of Cell Science 2005; 118: 723-32 (IF: 6.2)40. Hai-Bo Xing, Hong-Ming Pan, Yong Fang, Xiao-Yun Zhou, Qin Pan, Da Li. Construction of a tumor cell targeting non viral gene delivery vector with polyethylenimine modified with RGD sequence-containing peptide，oncology letters，2014,7（2）：487-492.(Correspondence author)2013IF 0.23741. The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer. Hu XT, Chen W, Wang D, Shi QL, Zhang FB, Liao YQ, Jin M, He C.（2008.2）Oncology Reports 42. High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas. Chen W, Lau SK, Fong D, Wang J, Wang E, Arber DA, Weiss LM, Huang Q. (2009.6) American Journal of Surgical Pathology 43. Knockdown of the novel proteasome subunit ADRM1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity. Chen W, Hu XT, Shi QL, Zhang FB, He C. (2009.2) Oncology Reports44. Therapy-related acute lymphoblastic leukemia with t(8;14)(q11;32) but not 11q23 abnormality. Chen W, Huang Q.（2009.2）Leukemia and Lymphoma 45. Complete absence of KSHV/HHV8 in post-transplant lymphoproliferative disorders. Chen W, Huang Q, Zuppan CW, Rowsell EH, Cao JD, Weiss LM, Wang J.（2009.5）American Journal of Clinical Pathology46. t(11;14) plasma cell disorder presents as a true non-secretory, non-producer multiple myeloma. Chen W, Namara MM, Kim Y, Huang Q（2009.6）Clinical Lymphoma & Myeloma 47. ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as “leukemic phase”. Lu Y, Zhao XH, Wang E, Chen W, Huang Q. （2009.8）Leukemia Research48. Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia. Chen W, Huang Q.(2009.11) Leukemia Research49. Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review. Chen W, Wang E, Lu Y, Gaal KK, Huang Q. (2010.1) American Journal of Clinical Pathology50. Detection of clonal lymphoid receptor gene rearrangements in langerhans cell histiocytosis. Chen W, Wang J, Wang E, Lu Y, Weiss LM, Huang Q. (2010.7) American Journal of Surgical Pathology 51. Zhou W, Zhu H, Chen W, Hu X, Pang X, Zhang J, Huang X, Fang B, He C. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus.(2011.5) Cancer Gene Therapy.52. Wang Kaifeng,Ye Shenglong,Song Lijie, Weng Yongqiang. The metastasis of hepatocarcinoma can be inhibited by T lymphocytes reconstitution in nude mice model Hepato-Gastroenterology. 2010, vol102-103: 1-653. Wang Kaifeng,Pan Hongming, Lou Fang, Fan Hui. The expression of FXR and regulated genes as prognostic factors in patients with primary liver cancer. Oral presentation in 70th the Japanese Cancer Association. Oct. 5,2011 E-3094.54. Wang Kaifeng, Loufang, Pan Hongming. EXPRESSION OF FXR,MDR3 AND MRP ARE RELATED TO THE METASTATIC POTENTIALITY OF HEPATICCARCINOMA. Poster Presentation in International Liver Cancer Association Fourth Annual Conference (ILCA,Canada) 2010.9 NO. P05755. Wang Kaifeng, Pan Wei, Liu Xiangguan, Wang Fei.The establishment of optimized geometry mathematical model of radiofrequency ablation in hepatic carcinoma. 获中国临床肿瘤学科学基金2011优秀论文三等奖56. Wang KF, Pan W, Wang F, Wang GF, Madhava P, Pan HM, Kong DX, Liu XG. Geometric optimization of a mathematical model of radiofrequency ablation in hepatic carcinoma. Asian Pac J Cancer Prev. 2013;14(10):6151-8.57. Pan H*, et al. Efficacy and Tolerability of Oxycodone Hydrochloride Controlled-Release Tablets in Moderate to Severe Cancer Pain. Clin Drug Invest,2007;27(4):259-257.58. Liua F, Yong H, Li W, Pan H*. Feasibility of the use of visible and near infrared spectroscopy to assess soluble solids content and pH of rice wines. J Food Engin,2007;83(3):430.59. Pan H*, Xu N, Guo Y, Lou F. A phase II study of oxaliplatin with ELF regimen in patients with advanced gastric cancer. J of clinical oncology, 2007 Jun.60. Meng Y, Pan H* et al. Catheterization-associated complications of intraperitoneal chemotherapy in advanced gastric cancer. World J Gastroenterol, 2004;10(9):1372-1374.61. Yao Q, Ye X, Gu J, Wang L, Fu T, Wang Y, Lai Y, Wang Y, Wang X, Jin H, Guo Y*. Protective effect of Curcumin on chemotherapy-induced intestinal dysfunction Int J Clin Exp Pathol 2013 (IF: 2.2)62. Sun J, Lu H, Wang X and Jin H*. MicroRNAs in hepatocellular carcinoma: regulation, function and clinical Implications. The Scientific World Journal: Gastroenterology 2013;2013:924206 (IF: 1.5)63. MaY, Wang X and Jin H*. Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int. J. Mol. Sci 2013 May 16;14(5):10307-31 (IF: 2.1)64. Liang Y, Wang X, So K, Lam Y and Li Z. Novel nucleolar isolation method reveals rapid response of human nucleolar proteomes to serum stimulation Journal of Proteomics 2012; 77:521-30 (IF: 4.9)65. Hong W, Wang X, Yu X, Chen B, Ding G and Zhang Y. Palatine tonsillar metastasis of lung cancer during chemotherapy Int J Clin Exp Pathol 2012;5(5):468-471 (IF: 2.2)66. Wang L, Chen S, Xue M, Zhong J, Wang X, Gan L, Lam E, Liu X, Zhang J, Zhou T, Yu J, Jin H and Si J. Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis Molecular Medicine 2012 May 9;18(1):389-400 (IF: 5.9)67. Zhang S, Jiang T, Feng L, Sun J, Lu H, Wang Q, Pan M, Huang D, Wang X, Wang L and Jin H. Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha Journal of Molecular Medicine 2012 Sep;90(9):1069-77 (IF: 5.2)68. Han W, Sun J, Feng L, Wang K, Li D, Pan Q, Chen Y, Jin W, Wang X, Pan H and Jin H. Autophagy Inhibition Enhances Daunorubicin-induced Apoptosis in K562 cells PLoS One 2011;e028491 (IF: 4.8)69. Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, Ge W, Feng L, Lin X, Wang XJ, Wang X, Jin H. EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells PLoS One 2011;6(6):e18691 (IF: 4.5)70. Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, Zhang J, Zhou T, Yu J, Si J, Wang L and Jin H. ZIC1 Is Downregulated through Promoter Hypermethylation, and Functions as a Tumor Suppressor Gene in Colorectal Cancer. PLoS One. 2011 Feb 15;6(2):e16916 （IF: 4.8）71. Shu XS, Geng H, Li L, Ying J, Ma C, Wang Y, Poon FF, Wang X, Ying Y, Yeo W, Srivastava G, Tsao SW, Yu J, Sung JJ, Huang S, Chan AT and Tao Q. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLoS One. 2011 Nov 8;6(11):e27346 (IF: 4.8)72. Li L, Tao Q, Jin H, Hasselt AV, Poon FF, Wang X, Zeng MS, Jia W, Zeng YX, Chan AT, Cao Y. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling, and is frequently silenced in nasopharyngeal carcinoma Clin Cancer Res. 2010;16(11):2949-58 (IF: 6.8)73. Liu X, Lam EK, Wang X, Zhang JB, Cheng YY, Lam YW, Ng EK, Yu J, Chan FK, Jin H and Sung JJ. Promoter hypermethylation mediates downregulation of thiamin receptor SLC19A3 in gastric cancer Tumor Biology 2009;Oct 7;30(5):242-248 (IF: 2.2)74. Wang LJ, Jin HC*, Wang X, Lam EK, Zhang JB, Liu X, Chan FK, Si JM, Sung JJ*. ZIC1 is downregulated through promoter hypermethylation in gastric cancer Biochem Bioph Res Com 2009;Feb 20;379(4):959-63 (IF: 2.7)75. Lee KY, Geng H, Ng KM, Yu J, van Hasselt A, Cao Y, Zeng YX, Wong AH, Wang X, et al. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene. 2008;Sep 4;27(39):5267-76. (IF: 7.2)76. Yu J, Tao Q, Cheung K, Jin H, Poon FF, Wang X., et al. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors Hepatology 2008;Auguest;48(2):508 (IF: 11.4)77. Jin H., Wang X., Wong AHY, Chan ATC, Cullen P., Tao Q. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proceedings of the National Academy of Sciences of USA 2007;Jul 24;104(30):12353 (IF: 9.5)78. Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo J, Hu X. Shikonin circumvents cancer multidrug resisatnce by induction of necroptosis. Molecular Cancer Therapeutics. 2007;6(5);1641- 1649. IF:4.879. Li L, Han W*, Gu Y, Qiu S, Lu Q, Jin J, Luo J, Hu X. Honokiol induces a necrotic cell death through mitochondrial permeability transition pore. Cancer Research. 2007;67 (10);4894-4903. *共同第一作者。IF:7.67280. Hu X, Han W, Li L. Targeting the Weak Point of Cancer by Induction of Necroptosis. Autophagy. 2007;3(5);490-492. IF:4.65781. Zhang K, Han W*, Zhang R, Xu X, Pan Q, Hu X. Phenylobacterium zucineum sp. nov., a facultative intracellular bacterium isolated from a human erythroleukemia cell line K562. Systematic and applied microbiology. 2007;30(3);207-212. *共同第一作者。IF:2.51482. Li L, Pan Q, Han W, Liu Z, Li L, Hu X. Schisandrin B Prevents Doxorubicin-induced Cardiotoxicity via Enhancing Glutathione Redox Cycling. Clinical Cancer Research. 2007; 13(22):6753-6760. IF:6.2583. Tian W, Xu D, Han W, He H, Cai H, Chen H, Zhou M, Chen J, Deng YC. Cyclophilin D modulates cell death transition from early apoptosis to programmed necrosis induced by honokiol. Int J Oncol. 2013 May;42(5):1654-63. doi: 10.3892/ijo.2013.1863. Epub 2013 Mar 22. IF:2.65784. Fu X, Meng Z, Liang W, Tian Y, Wang X, Han W, Lou G, Wang X, Lou F, Yen Y, Yu H, Jove R, Huang W. miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene. 2013 Sep 23. doi: 10.1038/onc.2013.385. [Epub ahead of print] IF:7.35785. Han W, Xie J, LI L, Liu z, Hu X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis. 2009,May,01;14(5):674-86. IF:4.06686. Ann-Lii Cheng,....Hongming Pan... Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25-34,2009.87. Pan Hongming, et al. A phase Ⅱstudy of oxaliplatin with ELF regimen in patients with advanced gastric cancer. June 5-8,2004, 40th annual meeting.ASCO88. Xu Ligong,…Pan hongming ,et al. Capecitabine combined with trastuzumab as first-line therapy in patients with HER2-overexpressing metastatic breast cancer. Annals of oncology . 2004,15,Suppl 3: 38.89. Pan hongming, et al.Oxaliplatin in combination with fluorouracil and leucovorin as the treatment of advanced gastro-intestinal carcinoma. Program/proceedings ASCO, Thirty-eighth annual meeting, May18-21,2002,Orlando,FL.90. Pan Hongming, et al. The chemopreventive effect of green tea and tea polyphenols on dimethlhydrazine-induced colorectal cancer in ICR mice. Program/proceedings ASCO, Thirty-fifth annual meeting, May15-18, 1999, Atlanta, GA.91. Ye Meng, Pan Hongming, Wang Haiyun, et al. Catheter associated Complications of Intraperitoneal Chemotherapy in Advanced Gastric Cancer. World J Gastroenterol ,2003.92. Pan Hongming, et al. Ultra-Cut Biopsy Guided by Ultrasonography for Liver Lesions: Experience of 392 Clinical Cases Journal of Zhejiang University SCIENCE Jul,2002。93. Yu Z, Peng S, Hong-Ming P, Kai-Feng W.Expression of Multi-drug Resistance-Related Genes MDR3 and MRP as Prognostic Factors in Clinical Liver Cancer Patients. Hepatogastroenterology. 2012 Jul-Aug;59(117):1556-9.94. 郑宇，潘宏铭 伊立替康联合靶向药物在晚期结直肠癌治疗中的应用。临床药物治疗杂志. 2012,10(3): 52-5795. 潘勤，潘宏铭*. 类人慢性粒细胞性白血病小鼠模型的建立. 中国病理生理杂志. 2013, 29(8):1530-15396. 潘勤，潘宏铭*. 类人慢性粒细胞性白血病小鼠模型的建立. 中国病理生理杂志. 2013, 29(8):1530-15397. 方勇，候琦，卢瑜. 异丹叶大黄素下调膀胱癌细胞Cyclin D1基因表达诱导G0/G1细胞周期阻滞的研究. 中国病理生理杂志.2013, 29（3）：442-448.98. 卢瑜，方勇*. 下调X连锁调亡抑制蛋白基因表达增强多西他赛诱导膀胱癌细胞凋亡的作用. 中国病理生理杂志. 2012, 28（3）：427-432.99. 方勇，吴金民，潘宏铭. Caspase-3抑制剂抑制长春碱诱导的人乳腺癌细胞凋亡及IκB-α降解. 中国病理生理杂志. 2009, 25(2): 215-219.100. 王凯峰 潘宏铭.癌痛药物治疗的新观念. 临床药物治疗杂志. 2012,10(4): 1-4101. 王凯峰,叶胜龙,宋丽杰,崔杰峰,翁永强,梁春敏,孙瑞霞,汤钊猷.负载不同转移潜能肝癌细胞exosomes的树突状细胞激活T淋巴细胞体外杀伤作用的初步研究. 中华肝脏病杂志. 2007,15(9):658-662102. 王凯峰, 叶胜龙,宋丽杰,翁永强, 梁春敏, 赵燕,高东梅,汤钊猷.不同转移潜能的小鼠肝癌淋巴道转移和淋巴管生成的研究. 中华肝脏病杂志. 2006,14(3): 187-191103. 王凯峰, 叶胜龙,薛琼, 宋丽杰,田波, 梁春敏,翁永强, 汤钊猷.T淋巴细胞免疫功能重建对小鼠肝癌转移的影响. 中华肝脏病杂志. 2005,13(6): 443-446104. 肾功能不全患者癌痛治疗观察 第七届全国癌症康复与姑息医学大会优秀病例一等奖（2011）105. 射频热疗后小鼠脾细胞分泌细胞因子的动态变化. 中国病理生理杂志，2006年6月106. 射频治疗对荷H22肝癌小鼠脾淋巴细胞免疫功能的影响癌症，2006年1月107. 射频热疗荷H22肝癌小鼠后淋巴细胞增殖及细胞毒性的动态变化. 中华微生物学和免疫学杂志，2005年9月108. 羟基喜树碱腹腔内给药的药代动力学研究。中国中药杂志，2005年10月109. 羟基喜树碱两种不同给药途径的药代动力学研究. 中国药科大学学报，2005年12月主要课题1. 基于联合化疗的射频热疗的开发与应用 横向课题2. 膜型超抗原表达系统的构建及其抗肿瘤作用 浙江省自然科学基金 2000.1-2003.123. NUP98-IQCG融合基因的功能研究 国家自然科学基金，项目编号30872945 2008.6-2011.64. 基于纳米技术表面改性射频治疗针的研制及其在肺部肿瘤治疗中的应用 浙江省重大科技专项重点社会发展项目 2010C13025 2010.1.1-2013.12.315. EGFR抑制剂诱导肺癌细胞保护性自噬及机制研究 国家自然科学基金81272593 2013.1-2016.126. PCDH17 通过JNK/Bcl-2 信号通路增强胃癌和结直肠癌细胞对 5-FU 敏感性的机制研究；项目来源：国家自然科学基金青年项目；项目编号：81301891 2014.1-2016.12；7. ZNF671: 一个新的胃癌相关抑癌基因 国家自然科学基金 81071963 2011-2013 8. 胃癌相关抑癌基因研究 教育部中央高校基本科研项目 2011-20129. EZH2对wnt信号通路的调控机制 浙江省钱江人才计划 2011R10073 2011-201210. 靶向治疗在肿瘤综合治疗中的合理运用 浙江省科技厅2012R10046-12 2012-201411. DNA羟甲基化在结直肠癌中的作用和调控机制 973 2012-201512. 胃癌发生过程中p21Ras异常活化的一种新机制 国家自然科学基金 81071652 2011-201313. EZH2调控wnt信号通路的新机制研究 浙江省自然科学基金 2012-201514. 基于表观遗传学定量检测技术的大肠癌监测方法 卫生部浙江省共建项目 2012-201415. 新胃癌抑制基因DTWD1的表达调控以及作用机制研究 教育部博士点专项基金-博导类 2012-2014辅助期大肠癌患者中医证侯临床转化性研究 浙江省科技厅2010C33140 2011-201316. YY1在肝癌形成和进展中的作用及其分子机制研究 浙江省自然科学基金2011-201317. 胃癌新辅助化疗的规范性应用浙江省科技厅2012R10046-07 2012-201418. 转移性肝癌射频消融的规范化治疗 浙江省科技厅 2012R10046-11 2012-201419. 乳腺癌综合诊治规范的推广研究 浙江省科技厅2012R10046-08 2012-201420. PUMA在肿瘤靶向治疗中的作用及其机制研究 浙江省科技厅2012R10046-15 2012-201421. 一种基于外周血微小RNA定量分析技术的大肠癌监测方法 浙江省卫生厅N20100555 2011-201322. Up-regulation of the novel oncogene PHI-1 represents a new mechanism of aberrant Ras activation in gastric cancer RGC-GRF香港研究资助局2008-201023. Subcellular localization of microRNAs: function and regulation RGC-GRF香港研究资助局2010-201224. The Proteomic Landscape of the Human Nucleolus during Senescence RGC-GRF香港研究资助局2007-200925. Proteomic study on nuclear reprogramming during cell differentiation RGC-GRF香港研究资助局 2008-201026. p53-auotophagy信号通路在肿瘤Warburg 效应中的调控作用及其分子机制；项目来源：浙江省自然科学基金青年项目；项目编号：LQ13H160008 2013.1-2015.1227. p27Kip1调控表皮生长因子受体(EGFR)基因表达的研究 项目来源：浙江省自然科学基金 2013年1月至2015年12月；项目编号：LY13H16001328. 抑制自噬在逆转 p53 -/-细胞对 5-Fu 耐药中的功能和机制研究，项目来源：浙江省自然科学基金 2013年1月至2015年12月；项目编号：LQ13H16000929. 异丹叶大黄素下调膀胱癌细胞的细胞周期蛋白D1基因的机制研究, 项目来源：浙江省中医药管理局 项目编号：2013ZB084，2013年7月至2015年12月30. 浙江省自然科学基金“新型非病毒转基因载体的构建及其在胃癌腹膜转移治疗中的应用研究”（项目编号Y2080134，2009.1-2010.12）31. 浙江省医药卫生科技计划“吉非替尼对晚期非小细胞肺癌患者免疫功能的影响” （项目编号2009B087，2009.6-2011.12）32. 国家自然科学基金（青年基金）“基于环糊精构建药物基因共携带靶向载体的结构优化及在肺癌治疗中的应用”（项目编号81001034，2011.1-2013.12）33. 纳米颗粒在不同转移潜能肝癌中的分泌 浙江省教育厅 Y20080384734. 肝癌射频治疗的优化研究 浙江大学青年教师交叉学科研究项目（985子课题资助）200904335. 数学模型在肝癌射频中的优化研究 2012年省医药卫生平台骨干人才计划36. miR-26a抑制炎症相关性结直肠癌的发生发展及其机制研究 2014国家自然基金面上项目37. 一类necroptosis诱导剂抗肿瘤干细胞研究 2010国家自然基金青年项目38. 紫草素及其衍生物诱导肿瘤细胞necroptosis分子机理研究 2010教育部博士点新教师基金39. 一类程序性坏死诱导剂－紫草素及其衍生物抗白血病干细胞研究 2010浙江省自然科学基金40. 基于病毒衣壳蛋白的智能型药物输送体系的构建及应用 2011浙江省科技厅社会公益项目Exosomes来源miRNA在肝癌转移中的功能分析 教育厅 Y201224441浙江省肿瘤学界泰斗 郑树 教授浙江省“求是特聘教授”金洪传 教授美国Loma Linda大学医学院血液肿瘤科主任 CS Chen教授美国City Hope大学城 Wendong Huang教授美国City Hope大学城 Xiyong Liu教授潘宏铭教授1997年在美国Loma Linda 大学肿瘤中心进修肿瘤内科学，2008年1月至2月在美国Mayo Clinic肿瘤中心做访问学者，接受肿瘤内科临床和国际多中心抗癌药物临床试验培训主要研究者（PI）。王娴副主任医师2002.1-2005.10于Institute of Toxicology & Genetics, Karlsruhe大学, 德国 博士后，2005.11--2007.07香港中文大学Research Associate，2007.08-2009.11香港城市大学Research Fellow。楼芳主治医师1999.1~1999.2赴罗马琳达医院进修，2000年1月赴美国CITY OF HOPE进修1年，学成归国。方勇副主任医师2011年3月起赴美国纽约大学医学院进修1年，学成回国。韩卫东副研究员2011年4月起赴美国CITY OF HOPE进修1年半，学成回国。李达副主任医师2013.5~2013.6在澳大利亚Cabrini医院进修。王凯峰副主任医师2013.3-2013.6赴伦敦帝国理工学院（Imperial College, London）进修腔道射频消融技术。陈薇博士2013.5-2013.7赴日本日本静冈县立综合病院进修学习。学科每年接受国内外访问交流学者近20人。科室成员多次受邀在国际会议上作专题报告。并与国外先进医疗中心如美国罗马琳达医学中心、约翰霍普金斯医学院、梅奥医学中心、英国帝国理工大学、纽约大学医学院等建立了密切的合作关系。